The FDA has granted clearance for an innovative blood test developed by Roche and Eli Lilly that aims to assist in the evaluation and diagnosis of Alzheimer’s disease. This marks a significant milestone as it is one of the first blood tests that can detect signs of Alzheimer’s pathology in adults as young as 40. The test is designed for use in both primary and specialty care settings, making it more accessible for early diagnosis of cognitive decline. Companies like Labcorp and Quest Diagnostics are set to offer these FDA-cleared tests, highlighting a promising shift toward less invasive diagnostic methods for Alzheimer’s.